NeuBase Therapeutics, Inc. announced the appointment of Todd P. Branning as Chief Financial Officer (CFO). Prior to joining NeuBase, Mr. Branning was CFO of Phathom Pharmaceuticals, Inc. Before that, he was Senior Vice President, CFO of Amneal Pharmaceuticals, Inc.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.378 USD | -3.20% |
|
-.--% | -48.93% |
06-27 | NeuBase Therapeutics, Inc. Announces Board Resignations | CI |
05-29 | NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+17.04% | 45.34B | |
+42.10% | 40.42B | |
-10.12% | 37.92B | |
+32.85% | 31.75B | |
-8.98% | 27.71B | |
+12.67% | 26.52B | |
+44.51% | 13.96B | |
+31.58% | 12.44B | |
-7.14% | 11.26B |
- Stock Market
- Equities
- O7P Stock
- NBSE Stock
- News NeuBase Therapeutics, Inc.
- NeuBase Therapeutics, Inc. Appoints Todd P. Branning as Chief Financial Officer